Candriam Luxembourg S.C.A. Buys 6,037 Shares of Humana Inc. (NYSE:HUM)

Candriam Luxembourg S.C.A. raised its stake in shares of Humana Inc. (NYSE:HUMGet Rating) by 33.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 23,845 shares of the insurance provider’s stock after purchasing an additional 6,037 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Humana were worth $11,061,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in HUM. Cordasco Financial Network grew its stake in Humana by 32.0% in the 3rd quarter. Cordasco Financial Network now owns 99 shares of the insurance provider’s stock valued at $39,000 after buying an additional 24 shares in the last quarter. Moors & Cabot Inc. grew its stake in Humana by 1.7% in the 3rd quarter. Moors & Cabot Inc. now owns 1,455 shares of the insurance provider’s stock valued at $567,000 after buying an additional 24 shares in the last quarter. B. Riley Wealth Management Inc. grew its stake in Humana by 5.0% in the 4th quarter. B. Riley Wealth Management Inc. now owns 546 shares of the insurance provider’s stock valued at $253,000 after buying an additional 26 shares in the last quarter. Orion Portfolio Solutions LLC grew its stake in Humana by 4.8% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 592 shares of the insurance provider’s stock valued at $230,000 after buying an additional 27 shares in the last quarter. Finally, Cribstone Capital Management LLC grew its stake in Humana by 2.3% in the 3rd quarter. Cribstone Capital Management LLC now owns 1,263 shares of the insurance provider’s stock valued at $491,000 after buying an additional 28 shares in the last quarter. 94.93% of the stock is owned by institutional investors and hedge funds.

In other Humana news, insider Timothy S. Huval sold 3,477 shares of the company’s stock in a transaction dated Thursday, April 28th. The shares were sold at an average price of $443.14, for a total value of $1,540,797.78. Following the sale, the insider now owns 5,768 shares in the company, valued at $2,556,031.52. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO William Kevin Fleming sold 3,210 shares of the company’s stock in a transaction dated Thursday, April 28th. The stock was sold at an average price of $449.68, for a total transaction of $1,443,472.80. Following the completion of the sale, the chief accounting officer now owns 884 shares in the company, valued at approximately $397,517.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,644 shares of company stock valued at $4,702,360. Insiders own 0.39% of the company’s stock.

Humana stock opened at $440.59 on Wednesday. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $55.73 billion, a PE ratio of 18.69, a P/E/G ratio of 1.30 and a beta of 0.86. The firm has a fifty day simple moving average of $441.98 and a two-hundred day simple moving average of $433.58. Humana Inc. has a twelve month low of $351.20 and a twelve month high of $472.68.

Humana (NYSE:HUMGet Rating) last issued its quarterly earnings data on Wednesday, April 27th. The insurance provider reported $8.04 EPS for the quarter, beating the consensus estimate of $6.79 by $1.25. The firm had revenue of $23.97 billion during the quarter, compared to the consensus estimate of $23.54 billion. Humana had a net margin of 3.51% and a return on equity of 17.27%. The company’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $7.67 earnings per share. As a group, equities analysts expect that Humana Inc. will post 24.65 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 29th. Stockholders of record on Thursday, June 30th will be paid a dividend of $0.7875 per share. This represents a $3.15 annualized dividend and a dividend yield of 0.71%. The ex-dividend date is Wednesday, June 29th. Humana’s dividend payout ratio (DPR) is 13.36%.

HUM has been the subject of a number of recent research reports. StockNews.com upgraded shares of Humana from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, April 20th. Zacks Investment Research upgraded shares of Humana from a “sell” rating to a “hold” rating and set a $445.00 price target for the company in a research report on Friday, February 4th. Truist Financial boosted their price target on shares of Humana from $460.00 to $490.00 in a research report on Thursday, April 7th. SVB Leerink reduced their price target on shares of Humana from $528.00 to $525.00 and set an “outperform” rating for the company in a research report on Thursday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on shares of Humana from $418.00 to $435.00 in a research report on Thursday, February 3rd. Seven investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $486.28.

Humana Company Profile (Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.